Verrica Pharmaceuticals
VRCA on Nasdaq. Market value $74m.
Should I look at this?
We have not checked this company yet
This is not advice.
Who owns it
1 long-term investor we follow owns it, unchanged from 1 last quarter. 43 funds in all.
| Fund | Value | Share of that fund | Change |
|---|---|---|---|
| Cannell CapitalJ. Carlo Cannell | $5m | 3.3% | Added |
Largest holders overall
- Caligan Partners LP$6m
- Cannell Capital$5mAdded
- Affinity Asset Advisors$4m
- Velan Capital Investment Management LP$3m
- Armistice Capital$3mCut
- Boothbay Fund Management$2m
- Vanguard Capital Management$2mAdded
- Mariner$1mAdded
- Geode Capital Management$845,656
- BlackRock$454,986Added
From 13F filings for the quarter ended 30 June 2026.
Big holders and activists
6 investors own more than 5%; 1 of them is pushing for change.
- Paul B ManningInsider or founderat least 49.9%(filed with 2 related holders)Since 25 November 2025
- at least 10.0%0.0 pts(filed with 1 related holder)Since 26 December 2025
What they said
On December 26, 2025, pursuant to the Purchase Agreement, the Issuer appointed Dr. Charles Frantzreb, a designee selected by Caligan, as a Class I member of the Board, effective immediately.
Read the filing - David JohnsonPassive investor10.0%Since 31 December 2024
- Affinity Asset Advisors, LLCPassive investorat least 5.5%+0.0 pts(filed with 1 related holder)Since 22 January 2026
- Affinity Healthcare Fund, LPPassive investor5.5%Since 25 November 2025
- Armistice Capital, LLCPassive investorat least 5.0%−1.8 pts(filed with 1 related holder)Since 31 December 2025
- Perceptive Advisors LLCPassive investorSold down below 5%Since 31 March 2025
| Holder | Stake | Since | |
|---|---|---|---|
Paul B Manning Insider or founder | at least 49.9% (filed with 2 related holders) | 25 November 2025 | |
at least 10.0%0.0 pts (filed with 1 related holder) | 26 December 2025 | What they saidOn December 26, 2025, pursuant to the Purchase Agreement, the Issuer appointed Dr. Charles Frantzreb, a designee selected by Caligan, as a Class I member of the Board, effective immediately. Read the filing | |
David Johnson Passive investor | 10.0% | 31 December 2024 | |
Affinity Asset Advisors, LLC Passive investor | at least 5.5%+0.0 pts (filed with 1 related holder) | 22 January 2026 | |
Affinity Healthcare Fund, LP Passive investor | 5.5% | 25 November 2025 | |
Armistice Capital, LLC Passive investor | at least 5.0%−1.8 pts (filed with 1 related holder) | 31 December 2025 | |
Perceptive Advisors LLC Passive investor | Sold down below 5% | 31 March 2025 |
From Schedule 13D and 13G filings: anyone owning more than 5% must file one.
What insiders did
In the last 12 months, 5 insiders bought $18m of shares on the open market.
- Rosenberg Noah L.CMOBought
- Date
- 18 August 2026
- Shares
- 2,030
- Price
- $4.92
- Value
- $9,988
- Kirby John J.Interim CFOBought
- Date
- 18 August 2026
- Shares
- 5,000
- Price
- $4.93
- Value
- $24,650
- Zawitz DavidChief Operating OfficerBought
- Date
- 17 August 2026
- Shares
- 6,000
- Price
- $4.98
- Value
- $29,880
- Rieger JaysonCEO and President, DirectorBought
- Date
- 17 August 2026
- Shares
- 5,000
- Price
- $4.91
- Value
- $24,550
- Rosenberg Noah L.CMOBought
- Date
- 17 August 2026
- Shares
- 4,200
- Price
- $4.91
- Value
- $20,622
- Rieger JaysonCEO and President, DirectorBought
- Date
- 14 August 2026
- Shares
- 20,000
- Price
- $5.06
- Value
- $101,200
- Zawitz DavidChief Operating OfficerBought
- Date
- 25 November 2025
- Shares
- 10,000
- Price
- $4.24
- Value
- $42,400
- Rieger JaysonCEO and President, DirectorBought
- Date
- 25 November 2025
- Shares
- 94,311
- Price
- $4.24
- Value
- $399,879
- Rosenberg Noah L.CMOBought
- Date
- 25 November 2025
- Shares
- 2,357
- Price
- $4.24
- Value
- $9,994
- Kirby John J.Interim CFOBought
- Date
- 25 November 2025
- Shares
- 3,536
- Price
- $4.24
- Value
- $14,993
| Date | Who | Did | Shares | Price | Value |
|---|---|---|---|---|---|
| 18 August 2026 | Rosenberg Noah L. CMO | Bought | 2,030 | $4.92 | $9,988 |
| 18 August 2026 | Kirby John J. Interim CFO | Bought | 5,000 | $4.93 | $24,650 |
| 17 August 2026 | Zawitz David Chief Operating Officer | Bought | 6,000 | $4.98 | $29,880 |
| 17 August 2026 | Rieger Jayson CEO and President, Director | Bought | 5,000 | $4.91 | $24,550 |
| 17 August 2026 | Rosenberg Noah L. CMO | Bought | 4,200 | $4.91 | $20,622 |
| 14 August 2026 | Rieger Jayson CEO and President, Director | Bought | 20,000 | $5.06 | $101,200 |
| 25 November 2025 | Zawitz David Chief Operating Officer | Bought | 10,000 | $4.24 | $42,400 |
| 25 November 2025 | Rieger Jayson CEO and President, Director | Bought | 94,311 | $4.24 | $399,879 |
| 25 November 2025 | Rosenberg Noah L. CMO | Bought | 2,357 | $4.24 | $9,994 |
| 25 November 2025 | Kirby John J. Interim CFO | Bought | 3,536 | $4.24 | $14,993 |
From Form 4 filings: insiders must report trades in their own company's shares within two days.
The deep dive
Everything above is arithmetic on public filings. The deep dive reads the last ten years of annual reports, the proxy statements, and the earnings calls, then argues the case the way Buffett, Klarman, and Hohn would, and checks every claim against the source.
- What the business is worth, as a range, and the margin of safety at today’s price
- Prices to start buying, buy, and buy hard
- The three things that would make this a mistake
- Every number footnoted to the filing it came from
Your first deep dive is free.
Not advice. Numbers on this page come from SEC filings and are updated each night; prices are updated again after the US market closes. The five-year figures are rounded.